Vir Biotechnology, Inc.
VIRNasdaq
$9.43
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +74.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4B
Enterprise Value
$919.1M
P/E
—
P/S
21.2
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
-32.4%
Dividend Yield
—
Revenue (TTM)
$65.5M
Net Income (TTM)
-$442.7M
Free Cash Flow (TTM)
-$449.6M
Gross Margin
—
Operating Margin
-720.8%
Net Margin
-676.0%
ROE
-54.5%
ROIC
-108.9%
Debt / Equity
—
Net Cash
$470.4M
Return 1Y
+71.8%
Company profile
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs, for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health.
- CEO
- George A. Scangos
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 580
- Headquarters
- California
- Website
- vir.bio
Earnings
VIR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue-$29,000.00↓ -101.0%
Diluted EPS-$0.85↓ -3.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $76.4M | $1.1B | $1.6B | $86.2M | $74.2M | $68.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$297.0M | $420.8M | $833.1M | -$684.3M | -$587.2M | -$479.3M |
| Net income | -$298.7M | $528.6M | $515.8M | -$615.1M | -$522.0M | -$438.0M |
| Diluted EPS | -$2.51 | $3.96 | $3.83 | -$4.59 | -$3.83 | -$3.16 |
| Operating cash flow | -$190.9M | -$47.6M | $1.7B | -$778.8M | -$446.4M | -$391.8M |
| Free cash flow | -$197.5M | -$69.4M | $1.6B | -$800.4M | -$453.7M | -$396.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -388.9% | 38.4% | 51.6% | -794.0% | -791.3% | -699.2% |
| Net margin | -391.1% | 48.3% | 31.9% | -713.8% | -703.4% | -638.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $2.4M | $12.4M | $3.0M | $1.2M | $240,000.00 | $64.1M | -$29,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$158.6M | -$231.3M | -$117.2M | -$139.5M | -$118.4M | -$173.4M | -$47.9M | -$132.3M |
| Net income | -$138.4M | -$213.7M | -$104.6M | -$121.0M | -$111.0M | -$163.1M | -$42.9M | -$125.7M |
| Diluted EPS | -$1.02 | -$1.56 | -$0.77 | -$0.88 | -$0.80 | -$1.17 | -$0.31 | -$0.85 |
| Operating cash flow | -$77.8M | -$171.5M | -$87.6M | -$78.1M | -$120.2M | -$167.6M | -$25.9M | -$132.4M |
| Free cash flow | -$78.5M | -$174.2M | -$89.6M | -$79.7M | -$122.8M | -$167.9M | -$26.2M | -$132.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -5158.7% | -9718.7% | -946.7% | -4602.5% | -9754.3% | -72267.9% | -74.8% | 456172.4% |
| Net margin | -4500.1% | -8979.7% | -845.2% | -3989.6% | -9139.9% | -67975.4% | -67.0% | 433431.0% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.